Meeting
2022 ASCO Genitourinary Cancers Symposium
GAMMA: Results from a phase II study for relapsed germ cell tumors using an oxaliplatin-based treatment regimen.
Authors
Kenrick Ng
Barts Health NHS Trust, London, United Kingdom
Kenrick Ng , Aaron Prendergast , Abigail Carter , Yathushan Yogeswaran , Susanna B. Alexander , Sarah Rudman , Han Hsi Wong , Constantine Alifrangis , Ewa Nowosinska , Daniel Berney , Jonathan Shamash
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT01782339
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 417)
DOI
10.1200/JCO.2022.40.6_suppl.417
Abstract #
417
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Salvage chemotherapy for relapsed germ cell tumors: A phase II trial of gemcitabine, paclitaxel, ifosfamide, and cisplatin (Gem-TIP).
First Author: Matthew James Wheater
Poster
2016 ASCO Annual Meeting
Phase II study of intraperitoneal paclitaxel plus S-1/oxaliplatin for gastric cancer with peritoneal metastasis: SOX+IP PTX trial.
First Author: Yoshiyuki Fujiwara
Poster
2022 ASCO Annual Meeting
Gemcitabine-docetaxel in patients with relapsed high-grade osteosarcoma after first-line treatment with high-dose ifosfamide: A retrospective multicenter study.
First Author: Maria Grazia Pionelli
Poster
2018 ASCO Annual Meeting
A phase II trial of bevacizumab-GemAOD regimen for newly diagnosed extranodal NK/T cell lymphoma.
First Author: Zhiming Li